Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Cachexia; Cancer
- Main trialPhase 2
- “The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients. The main questions it aims to answer are: Can the efficacy of ASCA101 in improving cachexia be evaluated based on changes in body weight measured by InBody after 12 weeks (3 cycles) of weekly administration, compared to baseline, for each dose group? Do participants experience adverse events during administration of ASCA101 and/or within 4 weeks after the end of administration? This clinical trial comprises two parts. \[Study 1. Active-Controlled,…”In the company’s words, NCT07168226 on ClinicalTrials.gov
Other drugs for Cachexia; Cancer
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- PonsegromabPfizer · Phase 2/3
- VisugromabCatalYm GmbH · Phase 2/3
- RilogrotugAVEO Pharmaceuticals, Inc. · Phase 2/3
- SXRNJiangsu Guiqiong Pharmaceutical Co., Ltd. · Phase 2
- DS010Dartsbio Pharmaceuticals Ltd. · Phase 1/2
Coming up1
- 30 Apr 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Apr 2028 | Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 | |
| Phase 1Completed | 29 Feb 2024 | Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026